key: cord-0764911-fx9y3hsh
authors: Stroever, Stephanie J.; Ostapenko, Daniel; Scatena, Robyn; Pusztai, Daniel; Coritt, Lauren; Nee, Paul
title: Medication utilization among COVID-19 patients in a large, national dataset: Cerner Real-World Data™
date: 2021-04-15
journal: Clin Ther
DOI: 10.1016/j.clinthera.2021.03.024
sha: 9518537d31b61693929a0a6f3ac900125db8fbaf
doc_id: 764911
cord_uid: fx9y3hsh

PURPOSE: The outbreak of the novel coronavirus (COVID-19) required clinicians to use knowledge of therapeutic mechanisms of established drugs to piece together treatment regimens. The purpose of this study is to examine the trends in medication utilization among COVID-19 patients across the United States using a national dataset. METHODS: We conducted a cross-sectional study of the COVID-19 cohort in the Cerner Real-World Data™ warehouse, which includes de-identified patient information for encounters associated with COVID-19 from December 1, 2019 through June 30, 2020. The primary variables of interest were medications given to patients during their inpatient COVID-19 treatment. We also collected demographics, calculated the proportion of patients with each medication, and stratified by demographic variables. FINDINGS: Our sample included 51,169 inpatients from every region of the United States. Males and females were equally represented, and the majority of patients were white and non-Hispanic. The largest proportion of patients were older than 45 years old. Steroids had the highest utilization among all patients (56.5%), followed by hydroxychloroquine (17.4%), tocilizumab (3.1%), and lopinavir/ritonavir (1.1%). We found substantial variation in medication utilization by region, race, ethnicity, sex, age and insurance status. IMPLICATIONS: Variations in medication use are likely attributable to multiple factors, including the timing of the pandemic by region in the United States and processes by which medications are introduced and disseminated. This study is the first of its kind to assess trends in medication utilization in a national dataset and is the first large descriptive study of pharmacotherapy in hospitalized COVID-19 patients. It provides an important glimpse into prescribing patterns during a novel pandemic.

The outbreak of the novel coronavirus (COVID-19) required clinicians to use knowledge of therapeutic mechanisms of established drugs to piece together treatment regimens. The purpose of this study is to examine the trends in medication utilization among COVID-19 patients across the United States using a national dataset.

We conducted a cross-sectional study of the COVID-19 cohort in the Cerner Real-World Data™ warehouse, which includes de-identified patient information for encounters associated with COVID-19 from December 1, 2019 through June 30, 2020. The primary variables of interest were medications given to patients during their inpatient COVID-19 treatment. We also collected demographics, calculated the proportion of patients with each medication, and stratified by demographic variables.

Our sample included 51,169 inpatients from every region of the United States. Males and females were equally represented, and the majority of patients were white and non-Hispanic. The largest proportion of patients were older than 45 years old. Steroids had the highest utilization among all patients (56.5%), followed by hydroxychloroquine (17.4%), tocilizumab (3.1%), and lopinavir/ritonavir (1.1%). We found substantial variation in medication utilization by region, race, ethnicity, sex, age and insurance status.

Variations in medication use are likely attributable to multiple factors, including the timing of the pandemic by region in the United States and processes by which medications are introduced and disseminated. This study is the first of its kind to assess trends in medication utilization in a national dataset and is the first large descriptive study of pharmacotherapy in hospitalized COVID-19 patients. It provides an important glimpse into prescribing patterns during a novel pandemic.

The first major outbreak of the novel coronavirus (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), was reported in Wuhan, China in December 2019. As the pandemic was intensifying across the globe, clinicians were caring for patients without proven effective treatments. As the virus was novel, there were no randomized controlled trials examining potential treatment options. [1] [2] [3] Thus, clinicians were required to use established knowledge of therapeutic mechanisms (Table 1 ) of existing drugs to piece together treatment regimens. 4 Two main strategies emerged as investigators and clinicians shared knowledge on the clinical presentation of the disease: inhibition of viral replication and treatment of the host immune response. [5] [6] [7] [8] Inhibition of viral replication in the early stage of infection may prevent disease progression and minimize the cytotoxic immune response (i.e. cytokine storm). Medications such as remdesivir (Gilead, Foster City, CA, USA) and lopinavir/ritonavir (AbbVie, Inc., North Chicago, IL, USA) were tapped for offlabel use early in the outbreak. 1, 2, 7, [9] [10] [11] [12] Both medications interfere with viral transcription, thus stalling replication.

The secondary surge of inflammatory cytokines in SARS-CoV-2 infection is associated with extensive lung injury and multiple organ dysfunction. 6 Medications such as tocilizumab (Genetech USA, Inc., San Francisco, CA, USA), designed to block T-cell activation or prevent cytokine release, have proven efficacy in other forms of cytokine-mediated disease. [13] [14] [15] Tocilizumab is a recombinant humanized monoclonal antibody to interleukin-6, approved to treat refractory rheumatoid arthritis. [13] [14] [15] Corticosteroids and glucocorticoids also prevent or reduce inflammation by inhibiting adhesion of neutrophils to endothelial cells. 16, 17 By binding corticosteroid receptors, they increase the production of anti-inflammatory proteins and decrease the expression of pro-inflammatory genes. Hydrocortisone and dexamethasone are glucocorticoids that are structurally and pharmacologically similar to endogenous cortisol and similarly suppress the immune response. 3, 16 Investigators and medical experts have released studies and guidelines for the treatment of COVID-19. [18] [19] [20] However, the extent of medication utilization across the United States to treat COVID-19 is widely unknown. It is likely that regional and institutional preferences have played a large role in treatment plans with little consensus on what works best. The purpose of this study is to examine the trends in medication utilization among COVID-19 patients across the United States using a national dataset. We hypothesize that medication use will vary across demographic characteristics of the sample.

Some of the variation may mimic the epidemiology of disease severity, as well as the pattern of distribution in the United States over time. Given the challenge of treating a new pathogen, it is important to look back at the trends in utilization to characterize how clinicians responded to the crisis for future outbreaks of novel diseases.

We conducted a cross-sectional study of the COVID-19 cohort in the Cerner Real-World Data™ warehouse, similar to Cerner's retired Health Facts® platform. 21 The warehouse includes clinical data extracted from the electronic medical records (EMR) of 62 health systems in the United States with which Cerner has a data use agreement. The dataset includes de-identified patient level information for encounters associated with COVID-19 from December 1, 2019 through June 30, 2020 ( Figure 1 ). Cerner de-identified the records using a complex algorithm and utilized Health Insurance Portability and Accountability Act (HIPAA) compliant operating policies to ensure patient privacy. We used only deidentified information in the secure HealtheDataLab™ to conduct our study, and it was exempt from Institutional Review Board oversight. 22 Participants We included all pediatric and adult patients in the Cerner COVID-19 dataset that met our inclusion criteria. We included patients in our sample if they 1) had an inpatient encounter type and 2)

were prescribed at least one medication. We excluded patients that were only seen in the emergency department or as an outpatient. We also excluded patients that did not receive any medication during their inpatient stay. Cerner included records according to unique encounters rather than persons. To sample at the individual patient level, we combined all inpatient encounter data using the unique person identifier ("personid") variable. Therefore, the unit of analysis for the study is the individual patient.

The primary variables of interest were medications given to patients during their inpatient COVID-19 treatment, including chloroquine, hydroxychloroquine, remdesivir, lopinavir/ritonavir, tocilizumab, hydrocortisone, dexamethasone, methylprednisolone, prednisolone, and prednisone. We selected these medications for investigation a priori according to previously cited evidence and hypotheses. In this dataset, we found that medications were associated with a generic name and/or a brand name(s), and some names included a dosage. Thus, we truncated the medication name to remove dosage and queried the dataset according to the Cerner Multum list of medication names. 23 We included all routes of administration though these medications are overwhelmingly administered intravenously or orally.

We collected medication utilization data as a dichotomous variable, with "1" meaning the patient ever received the medication during his or her inpatient encounter(s) for COVID-19. Importantly, Cerner populated the medications in the dataset from reconciliation events, ordering events, and/or administering events. We only counted the medication once per unique person id.

We also collected demographic variables including age, sex, race, ethnicity, payer status, and region of the United States. We included sex as a categorical variable with male, female, and other. We included race and ethnicity as categorical variables as well, with race categorized as white, black, Asian/Pacific Islander, Alaskan Native/American Indian, other, unknown, and mixed, and ethnicity as non-Hispanic, Hispanic, and unknown. The COVID-19 cohort included age as a continuous variable except for individuals under 18 years old (listed at 17 for everyone) and those over 90 years old (listed as 90 for everyone). We chose to categorize the remaining ages by approximately 10-year increments (i.e. 

We performed all statistical analyses with Python in a Jupyter Notebook. 25, 26 We utilized the Matplotlib version 3.3.1 library to visualize our results and pandas version 1.1.3 for data manipulation and analysis. 27,28 We calculated the proportion of patients with each medication and stratified by demographic variables. We qualitatively compared the distribution of each medication to the overall distribution of the sample.

The Cerner COVID-19 cohort included 117,496 unique persons that had a diagnosis code that could be associated with COVID-19 exposure or infection or a positive COVID-19 laboratory test ( Figure   3 ). Following exclusions, our final sample size was 51,169.

There was approximately the same proportion of male and female patients (Table 2) in the dataset, and the majority were white (55.8%) and non-Hispanic (64.9%). Additionally, the largest proportion of patients were older than 45 years old. This is consistent with the age groups most at risk for severe disease described early in the pandemic. 29-31 More than one-quarter of patients received Medicare benefits, while the other most prevalent payer status was private (25.0%) and non-insured (22.1%). Lastly, the regions with the highest contribution to the dataset included region 0 (16.3%), region 2 (14.4%), region 3 (15.9%), and region 9 (16.6%).

We present the distributions of each medication used in the sample in Tables 2 and 3 .

Supplemental Figures 1 through 6 display the proportion of medication use within demographic subgroups. As a class, steroids had the highest utilization among all patients (56.5%), followed by hydroxychloroquine (17.4%), tocilizumab (3.1%), and lopinavir/ritonavir (1.1%). The type of steroid prescribed was similar across dexamethasone (28.3%), methylprednisolone (31.2%), and prednisone (24.7%) while prednisolone and hydrocortisone were used much less frequently (3.3% and 12.2% respectively).

We did not find remdesivir within this dataset, nor choloroquine. Chloroquine may not have been readily available since hydroxychloroquine is a newer adaptation of the drug and more commonly available in the United States. Additionally, the Cerner team noted in communication to users (unpublished) that remdesivir was not included, because it was rarely recorded in the standard medication section (i.e. MAR) of the EMR. The medication was experimental and required a compassionate use designation early in the pandemic. Thus, hospitals recorded it in the clinical research (or similar) section of the EMR instead.

The distribution of hydroxychloroquine across demographic groups differed from the distribution of the sample in several notable ways (Table 2) . First, 53.8% of patients that took hydroxychloroquine were male though males made up only 48.6% of the sample. Additionally, white patients accounted for 45% of hydroxychloroquine use though they represented 55.8% of the sample.

There were also differences across age groups when compared with the sample distribution, and only 13.2% of hydroxychloroquine use was among patients without insurance though the group accounted for 22.1% of the sample. We also found a higher proportion of hydroxychloroquine use among patients in region 0 when compared to the sample distribution (25.4% and 16.3% respectively). 

The distribution of steroid utilization across demographic groups was generally consistent with the overall distribution (Table 3) . Medicare patients accounted for 33.2% and 32.0% of methylprednisolone and prednisone use, though they represented 28.4% of the sample. White patients also accounted for a higher proportion of dexamethasone, methylprednisolone, prednisone, and hydrocortisone use than the sample distribution. Alternatively, black patients accounted for less than the distribution for each steroid except for prednisolone. Lastly, patients < 18 years old accounted for 45.7% of prednisolone utilization though they represented only 9.1% of the sample.

There were also group differences in steroid utilization. We found a higher proportion of males took steroids than females, and more white patients were prescribed steroids compared to other race categories. There were differences in steroid use across all age groups, as well as among 46-75 year olds.

Steroid use was also highly variable across payer status and region.

There were several marked differences in the distribution of tocilizumab when compared to the distribution of the sample. Males accounted for 67.1% of the tocilizumab prescribed though the distribution of males in the sample is 48.6%. White patients accounted for only 38.2% of the tocilizumab though they represented 55.8% of the sample, while "other" races accounted for 23.8% of tocilizumab use but only 13.6% of the sample. Patients with unknown ethnicity used more tocilizumab compared to non-Hispanic patients, though there was a greater proportion of non-Hispanic patients in the sample.

The majority of the tocilizumab consumed was among patients over 45 years old and patients with private insurance or Medicare. Patients without insurance accounted for a lower proportion of tocilizumab use than the sample distribution (17.6% and 22.1% respectively).

We found that males used more tocilizumab than females, though the proportion of use was < 5% for both sexes. There was also a difference in tocilizumab use across races. There were differences in age groups, with the most notable differences between patients < 35 or > 76 years old compared to those between 36 and 75. Patients with private insurance (4.5%) also used more tocilizumab compared to other payer groups (< 2.8%). Lastly, patients in region 1 (7.3%) used more tocilizumab than other regions (< 4.5% ).

The distribution of this medication mirrored the differences seen in tocilizumab when compared to the full sample. A higher proportion of males accounted for lopinavir/ritonavir use than their distribution in the sample. White patients also accounted for less lopinavir/ritonavir use than their distribution in the sample, while patients with unknown race accounted for more (21.9% and 5.0%, respectively). The proportion of patients without insurance that used lopinavir/ritonavir was distinctly lower than their distribution in the sample (3.3% and 22.1% respectively), while patients in the "other non-government" group accounted for more (15.5% and 0.9% respectively). Lastly, the majority of lopinavir/ritonavir use was attributed to patients in region 0 (65.6%), though their distribution in the sample was 16.3%.

We found differences in lopinavir/ritonavir utilization across all demographic groups. However, the proportion of each demographic that used the medication was less than 2% in almost all groups. We found the greatest differences between races and regions with patients of unknown race using more lopinavir/ritonavir than other groups. Patients in region 0 and 5 also used more lopinavir/ritonavir than the other regions of the United States.

The purpose of this study was to assess medication utilization among COVID-19 inpatients across the United States during the first wave of the pandemic. Due to the novel nature of the virus, clinicians pieced together treatment strategies in the absence of a solid evidence base. We found substantial variation in medication utilization by region, race, ethnicity, sex, age and insurance status. 

The introduction of the novel coronavirus required early innovation and imagination among providers. The processes necessary for medication acquisition, prescribing, and administration may help explain the trends we see in this study. First, and most importantly, the medications repurposed for COVID-19 needed to be safe and demonstrate that the benefits outweighed the risks.

Hydroxychloroquine and lopinavir/ritonavir are both examples of medications that were used in the context of COVID-19 until the risks outweighed the perceived benefits. 12, 36 Availability is also a likely determinant of medication use for COVID-19. Several studies describe widespread disruptions in drug manufacturing, difficulties procuring inventory, and drug shortages as important barriers to patient treatment early in the pandemic. 37,38 Burry et al. note the "highly volatile state of prescribing" that stressed the system and led to quick changes in supply and demand with the release of new (and often conflicting) information. 39 Additionally, we hypothesize that drug cost contributed to variability in this sample. Individuals in the private insurance group used substantially more tocilizumab and hydroxychloroquine than those in other payer groups, while patients in the uninsured group used more steroids. This is a novel finding; to date, no studies have identified a role for payer status influencing inpatient drug prescription.

Equally important in medication utilization is stakeholder buy-in. Key opinion leaders are experts in their respective fields that can legitimize new treatment ideas and serve as sources of authority in complex situations. 39-41 Lopinavir/ritonavir use was greatest in regions 0 and 5. It is possible that the excess use in region 0 reflects the timing of pandemic and regional enthusiasm among key opinion leaders. Lopinavir/ritonavir held promise as an antiviral medication and was used with some frequency prior to the May New England Journal of Medical article describing no benefit. 12 This timing coincides with peak inpatient census in region 0. The higher use of tocilizumab in the northeast (regions 0 and 1) may also reflect the influence of regional enthusiasm for the use of this drug, with prominent institutions favoring early use in severe disease.

Additionally, key opinion leaders likely played an important role in the utilization of steroids among COVID-19 patients. Early global guidelines recommended against the use of steroids in this population. 20 However, it is clear from our data that steroids were repeatedly used among patients with COVID-19 before formal evidence became available. 3 Evidence suggests that key opinion leaders and support structures are stronger determinants of prescribing than clinical guidelines, particularly when working with new medications. 39 We hypothesize that frontline providers looked to key opinion leaders in the field for clinical decision making in the absence of a solid evidence base.

Lastly, the severity of disease likely played a role in medication utilization. We found greater use of hydroxychloroquine and tocilizumab in males than females, which may reflect the evidence that males were at greater risk of severe disease than females. 42 Additionally, patients in the unknown race and ethnicity categories used more of these medications. This group is difficult to interpret, though we hypothesize these individuals are in minority groups given the challenges with standard classification in a diverse country. [43] [44] [45] Limitations An important limitation of this study is its cross-sectional design that provides only a snapshot of medication utilization at a single point in time. We used the data descriptively and did not assess outcomes following medication use. The study design also prevented us from drawing conclusions from the data. Rather, we generated more hypotheses on medication utilization that need to be tested.

We were also limited by the structure of the dataset. The Cerner Real-World Data utilizes a complex algorithm to de-identify patients and ensure confidentiality. One of the primary ways encounters were de-identified was through date shifting [i.e. forwards or backwards in 7-day increments (+/-7, 14, 21, etc)]. As a result, we were unable to reliably trend medication use over time. We acknowledge that inferences related to time may be substantial and require cautious data interpretation.

Additionally, we found a discrepancy in the inpatient data that led us to exclude patients.

Notably, we found it unusual that more than 7,000 inpatients did not receive any medications during their inpatient stay. Upon inquiry with the Cerner COVID-19 data team, we learned that they continue to troubleshoot the dataset to determine the reason for this occurrence. We provide descriptive statistics for the excluded patients in Supplemental Table 1 . There are notable differences in the distribution of the excluded patients and study sample. There is a larger proportion of Hispanics and patients without insurance in the excluded sample. Additionally, more than 30% were from the Pacific coast. These are important to keep in mind in the interpretation of the findings from this study. None-the-less, the final sample provides important information that can be used to meet our objective.

Finally, the dataset did not include one of the leading medicines used to treat COVID-19. We know clinicians used remdesivir experimentally during the early surge of the pandemic. However, we were not able to assess the scope of the medication use in this study given limitations of the electronic medical record (described previously). It is also possible that electronic medical records inconsistently captured other experimental medications, and we may be underreporting them.

This study is the first of its kind to assess trends in medication utilization in a national dataset and is the first large descriptive study of pharmacotherapy in hospitalized COVID-19 patients. We provide an important glimpse into prescribing patterns during a novel pandemic, as well as generate many hypotheses that should be tested to further understand the determinants of medication use in global emergencies.

Norwalk Hospital. Lastly, we would like to acknowledge all of the healthcare providers in our network and across our country who have worked tirelessly to identify treatment strategies to save the lives of patients infected with this novel virus.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Note: Data are n (column %); to be interpreted as the proportion of medication users that were in each demographic catego that used steroids that were Non-Hispanic); † Steroids included dexamethasone, methylprednisolone, prednisolone, prednisone, and hydrocortisone. ‡ Regions determine patient's zip code 

Compassionate use of Remdesivir for patients with severe Covid-19

Characteristics and strength of evidence of COVID-19 studies registered on ClinicalTrials.gov

Dexamethasone in hospitalized patients with Covid-19 -Preliminary Report

Drug repurposing approach to fight COVID-19

COVID-19: Drug targets and potential treatments

Review of emerging pharmacotherapy for the treatment of Coronavirus Disease

Treatment considerations for COVID-19

Potential therapeutic agents against COVID-19: What we know so far

Arguments in favour of remdesivir for treating SARS-CoV-2 infections

Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19): a simplified summary

Remdesivir in adults with severe COVID-19: a randomised, doubleblind, placebo-controlled, multicentre trial. The Lancet

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Effective treatment of severe COVID-19 patients with tocilizumab

Tocilizumab treatment in COVID-19: A single center experience

Corticosteroids: A review of pertinent drug information for SARS-CoV-2. Presented at the Society of Infectious Disease Pharmacists

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

Infectious Diseases Society of America guideline on the treatment and management of patients with COVID-19. Infectious Disease Society of America

National Institutes of Health. Therapeutic management of patients with COVID-19. COVID-19 treatment guidelines

World Health Organization. Clinical Management of COVID-19: Interim Guidance

HealtheDataLaba cloud computing solution for data science and advanced analytics in healthcare with application to predicting multi-center pediatric readmissions

HealtheDataLab: Improving population health with a secure, nextgeneration research tool

Python Software Foundation

Self-reported vs administrative race/ethnicity data and study results

Discrepancies between published data on racial classification and self-reported race: evidence from the 2002 North Carolina live birth records

Public Health Rep Wash DC 1974

Kassamali Escobar, Z., Society of Infectious Disease Pharmacists. Chloroquine & hydroxychloroquine: A review of pertinent drug information for SARS-CoV-2

Society of Infectious Disease Pharmacists. Remdesivir (GS-5734): A review of pertinent drug information for SARS-CoV-2

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

The journey of remdesivir: from Ebola to COVID-19

Private (HMO, PPO) 12785 (25.0)

We would like to acknowledge Dr. Joann Petrini, Vice President for Innovation and Research at Nuvance Health for her solid support and facilitation of our partnership with the Cerner Learning Health Network. We would also like to acknowledge Mary Shah, MLS, AHIP, Medical Librarian and Archivist at